Showing results (761-770 of 5,687) with videos related to

Sort By:
Pageof 569
The Oncologist|May 8, 2025
Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case reportIlianna Galli-Vareia, Petr Szturz, Ioannis A Voutsadakis, et al.
The Oncologist|May 8, 2025
A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatmentVictor T G Lin, Esprit Ma, Neha Jain, et al.
The Oncologist|May 16, 2025
Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusionBrie M Chun, Sandra Youngworth, Vicki Abtin, et al.
The Oncologist|May 16, 2025
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of lifeDaniel Sentana-Lledo, Amelia Barnett, David J Einstein, et al.
The Oncologist|May 16, 2025
Influence of tamoxifen on ocular morphology and functionPiotr Strzalkowski, Alicja Strzalkowska, Maximiliane von der Ahe, et al.
The Oncologist|April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspectiveMerel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
The Oncologist|May 8, 2025
Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapiesShirish M Gadgeel, Otto Fajardo, Fabrice Barlesi, et al.
The Oncologist|March 31, 2025
Patient-reported continued benefits of pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United StatesDong Dai, Irene Pan, Klaus Freivogel, et al.
The Oncologist|March 26, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignanciesJibran Ahmed, Anne Knisely, Carlos Torrado, et al.
The Oncologist|November 9, 2025
Concordance in assessments between investigators and blinded independent central review (BICR) in hematology oncology clinical trials: a meta-analysisXiaoyu Tang, Yang Dang, Siying Han, et al.
Pageof 569